Intelligence Platform

Patents

Browse 1,444 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 7718629

Compositions and methods for inhibiting expression of Eg5 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue May 18 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7709456

Modulation of gene expression by oligomers targeted to chromosomal DNA

The Board of Regents of the University of Texas System · Granted Tue May 04 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7700274

Compositions and methods in cancer associated with altered expression of KCNJ9

Sagres Discovery, Inc. · Granted Tue Apr 20 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7696338

Immunotoxin fusion proteins and means for expression thereof

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 13 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7691824

Compositions and methods for inhibiting expression of a gene from the JC virus

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 06 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7691607

Expression system of NELL peptide

The Regents of the University of California · Granted Tue Apr 06 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7678890

Compositions and methods of treating disease with FGFR fusion proteins

Five Prime Therapeutics, Inc. · Granted Tue Mar 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7678552

Method for selecting therapeutic agents for cancer treatment

Precision Therapeutics, Inc. · Granted Tue Mar 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7662619

Sol-fusin: use of GP64-6His to catalyze membrane fusion

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Feb 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7655252

Antimicrobial nanoemulsion compositions and methods

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7648826

Detecting CYP24 expression level as a marker for predisposition to cancer

The Regents of the University of California · Granted Tue Jan 19 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7645441

Compositions and methods in cancer associated with altered expression of PRLR

Sagres Discovery, Inc. · Granted Tue Jan 12 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7635474

VEGF-binding fusion proteins

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 22 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7608268

Ferritin fusion proteins for use in vaccines and other applications

New Century Pharmaceuticals, Inc. · Granted Tue Oct 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7605131

EML4-ALK fusion gene

CUREGENE K.K. · Granted Tue Oct 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7604944

Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, n

Theravance, Inc. · Granted Tue Oct 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7605251

Compositions and methods for inhibiting expression of the PCSK9 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7601516

Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment o

Syntonix Pharmaceuticals, Inc. · Granted Tue Oct 13 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7598341

Molecules that selectively home to vasculature of premalignant or malignant lesions of the

The Regents of the University of California · Granted Tue Oct 06 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7598077

Compositions and methods for enhancing differential expression

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Oct 06 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7585653

Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, n

Theravance, Inc. · Granted Tue Sep 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7582745

Compositions and methods for inhibiting expression of Nav1.8 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7576065

Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concu

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 18 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7563593

Method for preparing cell cultures from biological specimens for assaying secreted factors

Precision Therapeutics, Inc. · Granted Tue Jul 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted